What is the recommended treatment for fibromyalgia?

Treatment for Fibromyalgia

Exercise is the only treatment with a strong recommendation for fibromyalgia, and should be the cornerstone of initial management, followed by a graduated approach adding patient education, psychological therapies, and pharmacotherapy only when non-pharmacological approaches fail. 1

Initial Management: Non-Pharmacological Therapies

First-Line: Exercise (Strong Recommendation)

• Aerobic and strengthening exercise is the only therapy with a "strong for" recommendation based on meta-analyses and should be initiated in all patients with fibromyalgia. 1
• Exercise improves pain, fatigue, sleep, and daily functioning—the key outcomes that impact quality of life. 1
• This is the single intervention with the strongest evidence base across all treatment modalities. 1

Patient Education

• Initial management must include patient education to provide reassurance, reduce unnecessary testing, and improve self-management abilities. 2, 3, 4
• Education helps patients understand that fibromyalgia is a chronic pain condition characterized by abnormal pain processing, not tissue damage requiring extensive investigation. 3

Second-Line: Additional Non-Pharmacological Therapies (Weak For)

If exercise and education are insufficient, add:

• Cognitive behavioral therapy (CBT): Particularly beneficial for patients with mood disorders and unhelpful coping strategies. 1, 3
• Multicomponent therapies: Combining aerobic exercise with at least one psychological therapy for at least 24 hours total duration, especially for severe fibromyalgia. 1, 5
• Physical therapies: Acupuncture or hydrotherapy as adjunctive treatments. 1
• Meditative movement therapies: Qigong, yoga, tai chi, and mindfulness-based stress reduction. 1

Third-Line: Pharmacological Management (All Weak For)

Pharmacotherapy should be reserved for severe pain or sleep disturbance that has not responded to non-pharmacological approaches. 1

FDA-Approved Medications (in the United States)

• Duloxetine (SNRI): Targets neurotransmitter modulation and central sensitization. 6, 3, 7
• Milnacipran (SNRI): Similar mechanism to duloxetine. 1, 3, 7
• Pregabalin (anticonvulsant): Addresses central sensitization. 1, 6, 3

Off-Label Medications with Weak Evidence

• Amitriptyline (low dose): Tricyclic antidepressant with pain modulation effects. 1, 2, 3
• Tramadol: Weak effect on pain, mainly short-term; use cautiously. 1, 6
• Cyclobenzaprine: Muscle relaxant with modest benefits. 1
• Gabapentin: Similar to pregabalin but not FDA-approved for fibromyalgia. 7
• Low-dose naltrexone: Emerging evidence for neuroinflammation modulation, but protocols not validated. 6, 2, 7

Fourth-Line: Multimodal Rehabilitation

For patients with severe disability despite the above interventions, consider a multimodal rehabilitation program combining multiple therapeutic modalities. 1

Critical Pitfalls to Avoid

Medications That Should NOT Be Used

• Opioids: No demonstrated benefit for fibromyalgia and carry high risk of abuse and severe side effects. 6, 3
• NSAIDs and acetaminophen: Limited efficacy and associated risks; generally not recommended. 2, 3
• Corticosteroids: Should be avoided due to lack of efficacy and side effect profile. 6
• Hormonal replacement therapy: Not indicated and carries risks. 6

Common Mistakes

• Starting with pharmacotherapy instead of exercise and education. 1
• Ordering extensive laboratory and radiological testing without clinical indication—only perform if needed to exclude treatable comorbidities. 1
• Using multiple medications simultaneously without first optimizing non-pharmacological approaches. 1

Graduated Treatment Algorithm

Stage 1: Exercise + Patient Education 1

Stage 2 (if insufficient effect): Add CBT or other non-pharmacological therapies 1

Stage 3 (if insufficient effect): Add pharmacotherapy (duloxetine, milnacipran, pregabalin, or low-dose amitriptyline) 1

Stage 4 (if severe disability persists): Multimodal rehabilitation program 1

Important Nuances

• All pharmacological treatments have only "weak for" recommendations, meaning the effect sizes are relatively modest across all medications. 1
• Treatment should be tailored to specific symptoms: psychological therapies for mood disorders, pharmacotherapy for severe pain or sleep disturbance. 1
• The combination of therapies is likely more effective than single-modality management, though this requires further research. 1, 7
• Shared decision-making with patients is essential given the modest benefits and potential side effects of most interventions. 1